Sarbani Ghosh Laskar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sarbani Ghosh Laskar has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Ashwini Budrukkar
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
5 shared publicationsPrathamesh Pai
Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
4 shared publicationsVedang Murthy
Advanced Centre for Treatment Research and Education in Cancer, Mumbai, Maharashtra, India
4 shared publicationsDevendra Chaukar
Department of Head and Neck Surgical Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India
3 shared publicationsJaiprakash Agarwal
Department of Radiation Oncology, Tata Memorial Hospital Centre, Parel, Mumbai, India
3 shared publicationsManju Sengar
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
3 shared publications
Latest Publications
- Open Access
- 1 January 2017
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 23 (1) , 104-108
Thyroid mass: Metastasis from nasopharyngeal cancer - an unusual presentation
Thyroid gland is an uncommon site of metastasis, and metastasis to the gland secondary to nasopharyngeal carcinoma is seldom seen. We were only able to identify eight reported cases in the literature. A 61-year-old man, diagnosed case of nasopharyngeal cancer–second primary ( first primary-oropharynx), was found to have a thyroid nodule on routine follow-up positron emission tomography-computed tomography (PET-CT) scan. There was no evidence of metastases at any other sites. The thyroid nodule was confirmed as metastatic carcinoma by fine needle aspiration cytology. He was treated with multimodal treatment comprising of surgery followed by reirradiation with concurrent chemotherapy. Subsequently, at the first follow-up (2 months after completion of all treatment), the patient remained asymptomatic, but the response assessment with PET-CT scan was suggestive of lung metastases with no evidence of locoregional disease. Although thyroid parenchymal metastasis is an uncommon occurrence and signifies a poor prognosis, in appropriately selected patients, aggressive therapy with reirradiation and chemotherapy may improve local control and quality of life.
- 1 January 2017
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 23 (1) , 104-108
Open AccessThyroid mass: Metastasis from nasopharyngeal cancer - an unusual presentation
Thyroid gland is an uncommon site of metastasis, and metastasis to the gland secondary to nasopharyngeal carcinoma is seldom seen. We were only able to identify eight reported cases in the literature. A 61-year-old man, diagnosed case of nasopharyngeal cancer–second primary ( first primary-oropharynx), was found to have a thyroid nodule on routine follow-up positron emission tomography-computed tomography (PET-CT) scan. There was no evidence of metastases at any other sites. The thyroid nodule was confirmed as metastatic carcinoma by fine needle aspiration cytology. He was treated with multimodal treatment comprising of surgery followed by reirradiation with concurrent chemotherapy. Subsequently, at the first follow-up (2 months after completion of all treatment), the patient remained asymptomatic, but the response assessment with PET-CT scan was suggestive of lung metastases with no evidence of locoregional disease. Although thyroid parenchymal metastasis is an uncommon occurrence and signifies a poor prognosis, in appropriately selected patients, aggressive therapy with reirradiation and chemotherapy may improve local control and quality of life.
- Open Access
- 1 January 2016
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 37 (01) , 47-52
Fluorodeoxyglucose-positron emission tomography in carcinoma nasopharynx: Can we predict outcomes and tailor therapy based on postradiotherapy fluorodeoxyglucose-positron emission tomography?
Background: Positron emission tomography-computed tomography (PET-CT) is an emerging modality for staging and response evaluation in carcinoma nasopharynx. This study was conducted to evaluate the impact of PET-CT in assessing response and outcomes in carcinoma nasopharynx. Materials and Methods: Forty-five patients of nonmetastatic carcinoma nasopharynx who underwent PET-CT for response evaluation at 10-12 weeks posttherapy between 2004 and 2009 were evaluated. Patients were classified as responders (Group A) if there was a complete response on PET-CT or as nonresponders (Group B) if there was any uptake above the background activity. Data regarding demographics, treatment, and outcomes were collected from their records and compared across the Groups A and B. Results: The median age was 41 years. 42 out of 45 (93.3%) patients had WHO Grade 2B disease (undifferentiated squamous carcinoma). 24.4%, 31.1%, 15.6, and 28.8% patients were in American Joint Committee on Cancer Stage IIb, III, Iva, and IVb. All patients were treated with neoadjuvant chemotherapy followed by concomitant chemoradiotherapy. Forty-five patients, 28 (62.2%) were classified as responders, whereas 17 (37.8%) were classified as nonresponders. There was no significant difference in the age, sex, WHO grade, and stage distribution between the groups. Compliance to treatment was comparable across both groups. The median follow-up was 25.3 months (759 days). The disease-free survival (DFS) of the group was 57.3% at 3 years. The DFS at 3 years was 87.3% and 19.7% for Group A and B, respectively (log-rank test, P < 0.001). Univariate and multivariate analysis revealed Groups to be the only significant factor predicting DFS (P value 0.002 and < 0.001, respectively). In Group B, the most common site of disease failure was distant (9, 53%). Conclusion: PET-CT can be used to evaluate response and as a tool to identify patients at higher risk of distant failure. Further, this could be exploited to identify patients who may need treatment intensification. This needs to be validated prospectively.
- 1 January 2016
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 37 (01) , 47-52
Open AccessFluorodeoxyglucose-positron emission tomography in carcinoma nasopharynx: Can we predict outcomes and tailor therapy based on postradiotherapy fluorodeoxyglucose-positron emission tomography?
Background: Positron emission tomography-computed tomography (PET-CT) is an emerging modality for staging and response evaluation in carcinoma nasopharynx. This study was conducted to evaluate the impact of PET-CT in assessing response and outcomes in carcinoma nasopharynx. Materials and Methods: Forty-five patients of nonmetastatic carcinoma nasopharynx who underwent PET-CT for response evaluation at 10-12 weeks posttherapy between 2004 and 2009 were evaluated. Patients were classified as responders (Group A) if there was a complete response on PET-CT or as nonresponders (Group B) if there was any uptake above the background activity. Data regarding demographics, treatment, and outcomes were collected from their records and compared across the Groups A and B. Results: The median age was 41 years. 42 out of 45 (93.3%) patients had WHO Grade 2B disease (undifferentiated squamous carcinoma). 24.4%, 31.1%, 15.6, and 28.8% patients were in American Joint Committee on Cancer Stage IIb, III, Iva, and IVb. All patients were treated with neoadjuvant chemotherapy followed by concomitant chemoradiotherapy. Forty-five patients, 28 (62.2%) were classified as responders, whereas 17 (37.8%) were classified as nonresponders. There was no significant difference in the age, sex, WHO grade, and stage distribution between the groups. Compliance to treatment was comparable across both groups. The median follow-up was 25.3 months (759 days). The disease-free survival (DFS) of the group was 57.3% at 3 years. The DFS at 3 years was 87.3% and 19.7% for Group A and B, respectively (log-rank test, P < 0.001). Univariate and multivariate analysis revealed Groups to be the only significant factor predicting DFS (P value 0.002 and < 0.001, respectively). In Group B, the most common site of disease failure was distant (9, 53%). Conclusion: PET-CT can be used to evaluate response and as a tool to identify patients at higher risk of distant failure. Further, this could be exploited to identify patients who may need treatment intensification. This needs to be validated prospectively.
- Open Access
- 1 January 2015
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 21 (3) , 296-297
Commentary
Indian J Palliat Care, is an peer-reviewed biomedical periodical of Indian Association of Palliative Care.
- 1 January 2015
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 21 (3) , 296-297
Open AccessCommentary
Indian J Palliat Care, is an peer-reviewed biomedical periodical of Indian Association of Palliative Care.
- Open Access
- 1 January 2015
- Published by Medknow in Indian Journal of Palliative Care
- Vol. 21 (1) , 26-27
Commentary
- 1 January 2015
- Published by Medknow in Indian Journal of Palliative Care
- Vol. 21 (1) , 26-27
Open AccessCommentary
- 15 September 2014
- Published by Wiley in Head & Neck
- Vol. 38 (2) , 202-207
Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial
Background The purpose of this study was to report the results of a phase III, 3‐arm, randomized trial comparing conventional radiotherapy (RT) to concurrent chemoradiotherapy (CRT) and accelerated RT in advanced head and neck squamous cell carcinoma (HNSCC). Methods One hundred eighty‐six of 750 planned patients were randomized to receive one of the following treatment plans: RT (66–70 Gy/2 Gy fraction/5 fractions weekly; CRT of weekly cisplatin (30 mg/m2) with the same RT dose; or accelerated RT alone of 66 to 70 Gy/2 Gy fraction/6 fractions weekly were available for analysis. The primary endpoint was locoregional control at 5 years. Results The mean follow‐up was 54 months. Among the 3 arms, CRT showed superior locoregional control (49%; p = .049). RT had lower grade ≥3 mucositis and late toxicity. Conclusion CRT is associated with significantly better locoregional control as compared to RT and accelerated RT with higher but acceptable acute and late toxicities. © 2015 Wiley Periodicals, Inc. Head Neck 38: 202–207, 2016
- 15 September 2014
- Published by Wiley in Head & Neck
- Vol. 38 (2) , 202-207
Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial
Background The purpose of this study was to report the results of a phase III, 3‐arm, randomized trial comparing conventional radiotherapy (RT) to concurrent chemoradiotherapy (CRT) and accelerated RT in advanced head and neck squamous cell carcinoma (HNSCC). Methods One hundred eighty‐six of 750 planned patients were randomized to receive one of the following treatment plans: RT (66–70 Gy/2 Gy fraction/5 fractions weekly; CRT of weekly cisplatin (30 mg/m2) with the same RT dose; or accelerated RT alone of 66 to 70 Gy/2 Gy fraction/6 fractions weekly were available for analysis. The primary endpoint was locoregional control at 5 years. Results The mean follow‐up was 54 months. Among the 3 arms, CRT showed superior locoregional control (49%; p = .049). RT had lower grade ≥3 mucositis and late toxicity. Conclusion CRT is associated with significantly better locoregional control as compared to RT and accelerated RT with higher but acceptable acute and late toxicities. © 2015 Wiley Periodicals, Inc. Head Neck 38: 202–207, 2016
- Open Access
- 1 July 2014
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 03 (03) , 145-146
Pathology of radiation toxicity and its implication on quality of life
Publication Date: 31 December 2020 (online) © 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 July 2014
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 03 (03) , 145-146
Open AccessPathology of radiation toxicity and its implication on quality of life
Publication Date: 31 December 2020 (online) © 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- Open Access
- 1 January 2014
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 4 (4) , 350-355
Postoperative interstitial brachytherapy in eyelid cancer: long term results and assessment of Cosmesis After Interstitial Brachytherapy scale
Purpose: To analyse feasibility and safety of postoperative interstitial brachytherapy (IBRT) in patients of eyelid cancer treated primarily by surgical excision. Material and methods: In this series, 8 patients with eyelid cancer were treated using postoperative interstitial...
- 1 January 2014
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 4 (4) , 350-355
Open AccessPostoperative interstitial brachytherapy in eyelid cancer: long term results and assessment of Cosmesis After Interstitial Brachytherapy scale
Purpose: To analyse feasibility and safety of postoperative interstitial brachytherapy (IBRT) in patients of eyelid cancer treated primarily by surgical excision. Material and methods: In this series, 8 patients with eyelid cancer were treated using postoperative interstitial...
- Open Access
- 1 January 2014
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 20 (3) , 169-170
Is Quality of Life "The Heart of The Issue" In Head and Neck Cancers?
- 1 January 2014
- Published by Scientific Scholar in Indian Journal of Palliative Care
- Vol. 20 (3) , 169-170
Open AccessIs Quality of Life "The Heart of The Issue" In Head and Neck Cancers?
- Open Access
- 1 January 2014
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 03 (01) , 005-007
Acute radiation toxicity in head and neck and lung malignancies
Publication Date: 31 December 2020 (online) © 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 January 2014
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 03 (01) , 005-007
Open AccessAcute radiation toxicity in head and neck and lung malignancies
Publication Date: 31 December 2020 (online) © 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 December 2012
- Published by Elsevier in Clinical Oncology
- Vol. 24 (10) , e180-e186
Hypofractionated Radiotherapy for T1N0M0 Glottic Cancer: Retrospective Analysis of Two Different Cohorts of Dose-fractionation Schedules from a Single Institution
- 1 December 2012
- Published by Elsevier in Clinical Oncology
- Vol. 24 (10) , e180-e186
Hypofractionated Radiotherapy for T1N0M0 Glottic Cancer: Retrospective Analysis of Two Different Cohorts of Dose-fractionation Schedules from a Single Institution